Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), & by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends & Forecasts to 2019

世界のコンパニオン診断市場:ポリメラーゼ連鎖反応(PCR)、In situ ハイブリダイゼーション(ISH)、免疫組織化学(IHC)など

◆タイトル:Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), & by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends & Forecasts to 2019
◆商品コード:MAM-BT-2698
◆調査・発行会社:MarketsandMarkets
◆発行日:2014年9月
◆ページ数:137
◆レポート形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:バイオ
◆販売価格オプション(消費税別)
Single user(1名使用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User(5名まで使用)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate licence(全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界のコンパニオン診断市場:ポリメラーゼ連鎖反応(PCR)、In situ ハイブリダイゼーション(ISH)、免疫組織化学(IHC)など"について調査・分析し、イントロダクション、エグゼクティブサマリー、プレミアムインサイト、市場概観、市場の成長要因、阻害要因、市場の機会と課題、産業動向、市場環境分析、市場の動態、技術別分析、用途別分析、需要先別分析、市場規模及び予測、競争状況、市場シェア分析、新製品発売、主要企業(ベンダー)分析等の情報をお届けいたします。

The global companion diagnostics market is expected to grow at a CAGR of 22.7% from 2014 to 2019. Factors such as rising need for personalized medicine in cancer treatment, growing adoption of companion diagnostics by the pharmaceutical industry, support from regulatory authorities, and emerging technologies such as next-generation sequencing (NGS) are expected to boost the global companion diagnostics market.

Among technologies, PCR is the most preferred test in the companion diagnostics market, which accounted for a share of 65.5% in 2014. This large share can be attributed to its ease of use, better results, faster turnaround time, and cost-effective solutions. The companion diagnostics market is expected to gain a larger market share in neurology and new oncology applications (leukemia, prostate cancer, and ovarian cancer) due to its efficient detection of biomarkers. Moreover, with the advancement in the bioinformatics field, NGS-based tests have the capability to target multiple genomes simultaneously and are likely to take over the existing technologies in the companion diagnostics market. The need for personalized medicine is increasing and it has gained importance in the research and medical centers, hospitals, and CROs. In the coming years, Asia is expected to be the key growth area in this market.

However, growth of this market is hampered by the non-validated home brew tests that account for a large market share due to its low costs and minimal approval procedures. Moreover, uncertain reimbursement and coverage policies restrict the growth of the global companion diagnostic market, thus limiting the commercialization process.

Reasons to Buy the Report

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on product portfolios of the top players in the companion diagnostics market. The report analyzes the companion diagnostics market by technology, application, end-user, and geography
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the companion diagnostics market
• Competitive Assessment: In-depth assessment of the market strategies, geographical and business segments, and product portfolios of the leading players in the companion diagnostics market
• Market Development: Comprehensive information about the emerging markets. The report analyzes the market for various companion diagnostics tests/kits across geographies
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the companion diagnostics market

【レポートの目次】

Table of Contents

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKETS COVERED 14
1.3 STAKEHOLDERS 15
1.4 MARKET SCOPE 15

2 RESEARCH METHODOLOGY 17
2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET CRACKDOWN AND DATA TRIANGULATION 21
2.3 MARKET SHARE ESTIMATION 21
2.3.1 KEY DATA TAKEN FROM SECONDARY SOURCES 21
2.3.2 KEY DATA FROM PRIMARY SOURCES 22
2.3.3 KEY INDUSTRY INSIGHTS 22
2.3.4 ASSUMPTIONS 23

3 EXECUTIVE SUMMARY 24

4 PREMIUM INSIGHTS 27

5 MARKET OVERVIEW 31
5.1 INTRODUCTION 32
5.2 EVOLUTION 32
5.3 MARKET SEGMENTATION 33
5.3.1 COMPANION DIAGNOSTICS MARKET 33
5.4 MARKET DYNAMICS 34
5.4.1 MARKET DRIVERS 35
5.4.1.1 Regulatory bodies encouraging implementation of companion diagnostics 35
5.4.1.2 Rising demand for targeted cancer treatment & tailored drugs ensure robust market growth in companion diagnostic tests 35
5.4.1.3 Growing adoption of companion diagnostics by pharmaceutical companies & reference laboratories to boost the market 36
5.4.2 MARKET RESTRAINTS 37
5.4.2.1 Reimbursement scenarios in different regions hamper the companion diagnostics market growth 37
5.4.2.2 Laboratory developed tests (home brew tests) affect adoption of companion diagnostic tests 37
5.4.3 MARKET OPPORTUNITIES 38
5.4.3.1 Emerging technologies such as next-generation sequencing (NGS) likely to stimulate the companion diagnostics market 38
5.4.3.2 Increasing scope for companion diagnostics in other cancer indications (ovarian, leukemia, prostate) & neurology 39

6 INDUSTRY TRENDS 41
6.1 PORTER’S FIVE FORCES ANALYSIS 41
6.1.1 THREAT FROM NEW ENTRANTS 41
6.1.2 THREAT FROM SUBSTITUTES 42
6.1.3 BARGAINING POWER OF SUPPLIERS 42
6.1.4 BARGAINING POWER OF BUYERS 42
6.1.5 INTENSITY OF COMPETITIVE RIVALRY 42
6.2 STRATEGIC BENCHMARKING 43
6.2.1 TECHNOLOGY INTEGRATION & PRODUCT ENHANCEMENT 43

7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY APPLICATIONS 44
7.1 INTRODUCTION 45
7.2 BREAST CANCER 47
7.3 LUNG CANCER 48
7.4 COLORECTAL CANCER 49
7.5 MELANOMA 50
7.6 GASTRIC CANCER 51
7.7 OTHER INDICATIONS (PROSTATE CANCER, OVARIAN CANCER, LEUKEMIA, NEUROLOGICAL, AND INFECTIOUS DISEASES) 51

8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 53
8.1 INTRODUCTION 54
8.2 POLYMERASE CHAIN REACTION (PCR) 54
8.3 IN-SITU HYBRIDIZATION (ISH) 55
8.4 IMMUNOHISTOCHEMISTRY (IHC) 56
8.5 OTHER TECHNOLOGIES (NGS,MULTIPLEX ASSAY, & MAB) 58

9 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER 59
9.1 INTRODUCTION 60
9.2 PHARMACEUTICAL COMPANIES 61
9.2.1 ACCURATE IDENTIFICATION & RECRUITMENT OF PARTICIPANTS IN CLINICAL TRIALS 61
9.2.2 PHARMACEUTICAL COMPANIES UNDERWENT PARTNERSHIPS & COLLABORATIONS WITH COMPANION DIAGNOSTICS MANUFACTURERS 62
9.2.3 BREAST CANCER & NON-SMALL CELL LUNG CANCER (NSCLC) THE MAJOR FOCUS AREAS FOR PHARMACEUTICAL COMPANIES 62
9.3 REFERENCE LAB 64
9.3.1 IMPORTANCE OF REFERENCE LABORATORIES IN GLOBAL COMPANION DIAGNOSTICS MARKET 64
9.4 OTHER END-USERS (CRO, PHYSICIANS, HOSPITALS & ACADEMIC MEDICAL CENTERS) 66

10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY GEOGRAPHY 68
10.1 INTRODUCTION 69
10.2 NORTH AMERICA 70
10.2.1 KEY PLAYERS FOCUSING ON COMPANION DIAGNOSTICS FOR BREAST AND LUNG CANCER 72
10.2.2 FDA INITIATIVES IN THE U.S. TO ENCOURAGE SIGNIFICANT ADOPTION OF COMPANION DIAGNOSTICS 73
10.2.3 ADOPTION OF PAY-FOR-PERFORMANCE PROGRAM STIMULATES PAYORS TO REIMBURSE FOR COMPANION DIAGNOSTIC TESTS 73
10.2.4 FOCUS ON PERSONALIZED MEDICINE IS A MAJOR DRIVER FOR COMPANION DIAGNOSTICS 73
10.3 EUROPE 78
10.3.1 EMA SUPPORTS THE DEVELOPMENT OF COMPANION DIAGNOSTIC TESTS 80
10.3.2 RISING INCIDENCE OF BREAST CANCER IN EUROPE 81
10.3.3 FRAGMENTED REIMBURSEMENT POLICY IN EUROPE HINDERING IN VITRO DIAGNOSTIC MANUFACTURERS FROM INVESTING IN COMPANION DIAGNOSTIC TESTS 81
10.4 ASIA 86
10.4.1 REGULATORY & REIMBURSEMENT FACTORS AFFECT PENETRATION OF COMPANION DIAGNOSTICS IN ASIA 87
10.5 REST OF THE W0RLD 92

11 COMPETITIVE LANDSCAPE 98
11.1 OVERVIEW 98
11.2 MARKET SHARE ANALYSIS, GLOBAL COMPANION DIAGNOSTICS MARKET 99
11.3 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS 102
11.4 MERGER AND ACQUISITIONS 103
11.5 NEW PRODUCT LAUNCHES 104
11.6 EXPANSION 105

12 COMPANY PROFILES 106
12.1 INTRODUCTION 106
12.2 ABBOTT LABORATORIES, INC. 106
12.3 AGILENT TECHNOLOGIES, INC. 109
12.4 BIOMÉRIEUX 113
12.5 BIOGENEX LABORATORIES 115
12.6 DANAHER CORPORATION 116
12.7 GE HEALTHCARE 118
12.8 MYRIAD GENETICS, INC. 121
12.9 QIAGEN N.V. 124
12.10 ROCHE DIAGNOSTICS 128
12.11 THERMO FISHER SCIENTIFIC, INC. 133
*Details on Business Overview, Products & Services, Key Strategy, & Recent Developments might not be captured in case of unlisted companies.

List Of Tables (60)

TABLE 1 INCREASING NEED FOR TARGETED TREATMENT IN ONCOLOGY IS PROPELLING THE GLOBAL COMPANION DIAGNOSTICS MARKET 36
TABLE 2 REIMBURSEMENT ISSUES HAMPER GROWTH OF COMPANION DIAGNOSTICS MARKET 38
TABLE 3 ADVANCED TECHNOLOGIES LIKELY TO STIMULATE COMPANION DIAGNOSTICS MARKET GROWTH 40
TABLE 4 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 46
TABLE 5 COMPANION DIAGNOSTICS MARKET SIZE FOR BREAST CANCER, BY GEOGRAPHY,
2012–2019 ($MILLION) 47
TABLE 6 COMPANION DIAGNOSTICS MARKET SIZE FOR LUNG CANCER, BY GEOGRAPHY,
2012–2019 ($MILLION) 48
TABLE 7 COMPANION DIAGNOSTICS MARKET SIZE FOR COLORECTAL CANCER,
BY GEOGRAPHY, 2012–2019 ($MILLION) 49
TABLE 8 COMPANION DIAGNOSTICS MARKET SIZE FOR MELANOMA, BY GEOGRAPHY,
2012–2019 ($MILLION) 50
TABLE 9 COMPANION DIAGNOSTICS MARKET SIZE FOR GASTRIC CANCER, BY GEOGRAPHY, 2012–2019 ($MILLION) 51
TABLE 10 COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER INDICATIONS,
BY GEOGRAPHY, 2012–2019 ($MILLION) 52
TABLE 11 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012–2019 ($MILLION) 54
TABLE 12 COMPANION DIAGNOSTICS MARKET SIZE FOR POLYMERASE CHAIN REACTION,
BY GEOGRAPHY, 2012–2019 ($MILLION) 55
TABLE 13 COMPANION DIAGNOSTICS MARKET SIZE FOR IN-SITU HYBRIDIZATION,
BY GEOGRAPHY, 2012–2019 ($MILLION) 56
TABLE 14 COMPANION DIAGNOSTICS MARKET SIZE FOR IMMUNOHISTOCHEMISTRY,
BY GEOGRAPHY, 2012–2019 ($MILLION) 57
TABLE 15 COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES,
BY GEOGRAPHY, 2012–2019 ($MILLION) 58
TABLE 16 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 61
TABLE 17 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY GEOGRAPHY, 2012–2019 ($MILLION) 62
TABLE 18 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABS,
BY GEOGRAPHY, 2014–2019 ($MILLION) 65
TABLE 19 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY GEOGRAPHY, 2014–2019 ($MILLION) 66
TABLE 20 COMPANION DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY,
2012–2019 ($MILLION) 69
TABLE 21 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 72
TABLE 22 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 74
TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY APPLICATION, 2012–2019 ($MILLION) 74
TABLE 24 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY APPLICATION, 2012–2019 ($MILLION) 75
TABLE 25 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY APPLICATION, 2012–2019 ($MILLION) 75
TABLE 26 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012–2019 ($MILLION) 76
TABLE 27 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY TECHNOLOGY, 2012–2019 ($MILLION) 76
TABLE 28 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY TECHNOLOGY, 2012–2019 ($MILLION) 77
TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY TECHNOLOGY, 2012–2019 ($MILLION) 77
TABLE 30 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 80
TABLE 31 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 82
TABLE 32 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY APPLICATION, 2012–2019 ($MILLION) 82
TABLE 33 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY APPLICATION, 2012–2019 ($MILLION) 83
TABLE 34 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY APPLICATION, 2012–2019 ($MILLION) 83
TABLE 35 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012–2019 ($MILLION) 84
TABLE 36 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY TECHNOLOGY, 2012–2019 ($MILLION) 84
TABLE 37 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY TECHNOLOGY, 2012–2019 ($MILLION) 85
TABLE 38 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY TECHNOLOGY, 2012–2019 ($MILLION) 85
TABLE 39 ASIA: COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 88
TABLE 40 ASIA: COMPANION DIAGNOSTICS MARKET SIZE, BY END USERS,
2012–2019 ($MILLION) 88
TABLE 41 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY APPLICATION, 2012–2019 ($MILLION) 89
TABLE 42 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES,
BY APPLICATION, 2012–2019 ($MILLION) 89
TABLE 43 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY APPLICATION, 2012–2019 ($MILLION) 90
TABLE 44 ASIA: COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012–2019 ($MILLION) 90
TABLE 45 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY TECHNOLOGY, 2012–2019 ($MILLION) 91
TABLE 46 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES,
BY TECHNOLOGY, 2012–2019 ($MILLION) 91
TABLE 47 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY TECHNOLOGY, 2012–2019 ($MILLION) 92
TABLE 48 ROW: COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 93
TABLE 49 ROW: COMPANION DIAGNOSTICS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 93
TABLE 50 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY APPLICATION, 2012–2019 ($MILLION) 94
TABLE 51 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES,
BY APPLICATION, 2012–2019 ($MILLION) 94
TABLE 52 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY APPLICATION, 2012–2019 ($MILLION) 95
TABLE 53 ROW: COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012–2019 ($MILLION) 95
TABLE 54 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY TECHNOLOGY, 2012–2019 ($MILLION) 96
TABLE 55 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY TECHNOLOGY, 2012–2019 ($MILLION) 96
TABLE 56 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY TECHNOLOGY, 2012–2019 ($MILLION) 97
TABLE 57 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS, 2011–2014 102
TABLE 58 MERGER AND ACQUISITIONS, 2011–2014 104
TABLE 59 NEW PRODUCT LAUNCHES, 2011–2014 105
TABLE 60 EXPANSION, 2011–2014 105

List Of Figures (44)

FIGURE 1 RESEARCH METHODOLOGY 18
FIGURE 2 BOTTOM-UP APPROACH 19
FIGURE 3 TOP-DOWN APPROACH 19
FIGURE 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 20
FIGURE 5 CDX TECHNOLOGY MARKET SNAPSHOT (2014 VS. 2019): NGS TECHNOLOGY IS EXPECTED TO DRIVE THE GLOBAL COMPANION DIAGNOSTICS MARKET IN THE COMING YEARS 24
FIGURE 6 GLOBAL COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014 25
FIGURE 7 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE, 2014 26
FIGURE 8 ATTRACTIVE MARKET OPPORTUNITIES IN THE GLOBAL COMPANION DIAGNOSTICS MARKET 27
FIGURE 9 BREAST CANCER SEGMENT IS EXPECTED TO HOLD THE LARGEST MARKET SHARE IN 2014 28
FIGURE 10 ASIA IS EXPECTED TO WITNESS THE HIGHEST GROWTH IN THE COMING YEARS 29
FIGURE 11 GLOBAL COMPANION DIAGNOSTIC MARKET, BY GEOGRAPHY,
2014 & 2019 ($MILLION) 29
FIGURE 12 GLOBAL COMPANION DIAGNOSTICS TECHNOLOGY MARKET, BY GEOGRAPHY,
2014 ($MILLION) 30
FIGURE 13 ASIAN COMPANION DIAGNOSTICS MARKET IS EXPECTED TO GROW AT A CAGR OF 24.3% DURING THE FORECAST PERIOD 30
FIGURE 14 TECHNOLOGY ADVANCEMENTS PLAY IMPORTANT ROLE IN COMPANION DIAGNOSTICS 32
FIGURE 15 COMPANION DIAGNOSTICS MARKET SEGMENTATION: BY TECHNOLOGY, APPLICATION, & END USER 33
FIGURE 16 COMPANION DIAGNOSTICS GAINED INCREASING DEMAND IN THE ONCOLOGY SEGMENT 34
FIGURE 17 PORTER’S FIVE FORCES ANALYSIS 41
FIGURE 18 STRATEGIC BENCHMARKING: ROCHE AND AGILENT TECHNOLOGIES, INC. LARGELY ADOPTED INORGANIC GROWTH STRATEGIES FOR TECHNOLOGY INTEGRATION AND PRODUCT ENHANCEMENT 43
FIGURE 19 THE COMPANION DIAGNOSTICS APPLICATIONS MARKET WILL BE DRIVEN BY THE GROWTH IN INCIDENCE & PREVALENCE OF BREAST AND LUNG CANCER 45
FIGURE 20 LUNG CANCER IS EXPECTED TO HAVE A LARGER MARKET SHARE IN THE FUTURE 46
FIGURE 21 PHARMACEUTICAL FIRMS DOMINATE END-USER MARKET, REFERENCE LABS SHOW HIGHEST GROWTH 60
FIGURE 22 ADOPTION OF COMPANION DIAGNOSTICS GROWING SIGNIFICANTLY AMONG PHARMACEUTICAL COMPANIES, REFERENCE LABORATORIES 60
FIGURE 23 PHARMACEUTICAL COMPANIES IN NORTH AMERICA: ARE THE MAJOR END USERS OF COMPANION DIAGNOSTICS 63
FIGURE 24 REFERENCE LABORATORIES IN NORTH AMERICA ARE CONSIDEREDTO BE THE SECOND LARGEST END USERS OF COMPANION DIAGNOSTICS 64
FIGURE 25 COMPANION DIAGNOSTICS TESTS ARE GAINING IMPORTANCE IN ACADEMIC MEDICAL CENTERS AND HOSPITALS DUE TO THEIR GROWTH POTENTIAL 66
FIGURE 26 ASIA IS EXPECTED TO BE THE FASTEST-GROWING MARKET FOR COMPANION DIAGNOSTICS 69
FIGURE 27 RISING PREVALENCE OF LIFE-THREATENING DISEASES TO DRIVE MARKET GROWTH IN NORTH AMERICA 71
FIGURE 28 EUROPE COMMANDS ONE-THIRD OF THE GLOBAL COMPANION DIAGNOSTICS MARKET 79
FIGURE 29 COMPANIES ADOPTED COLLABORATIONS/PARTNERSHIPS/AGREEMENTS AS THE KEY GROWTH STRATEGY OVER THE LAST THREE YEARS 98
FIGURE 30 TOP 5 PLAYERS OCCUPY 86% SHARE OF COMPANION DIAGNOSTICS MARKET (2013) 99
FIGURE 31 BATTLE FOR MARKET SHARE: PARTNERSHIPS, COLLABORATIONS, AGREEMENTS WERE PREFERRED STRATEGIES 101
FIGURE 32 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW 106
FIGURE 33 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 109
FIGURE 34 SWOT ANALYSIS 112
FIGURE 35 BIOMERIUX : BUSINESS OVERVIEW 113
FIGURE 36 DANAHER CORPORATION : BUSINESS OVERVIEW 116
FIGURE 37 GE HEALTHCARE : BUSINESS OVERVIEW 118
FIGURE 38 MYRIAD GENETICS : BUSINESS OVERVIEW 121
FIGURE 39 QIAGEN N.V. : BUSINESS OVERVIEW 124
FIGURE 40 SWOT ANALYSIS 127
FIGURE 41 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 128
FIGURE 42 SWOT ANALYSIS 132
FIGURE 43 THERMO FISHER SCIENTIFIC INC. : BUSINESS OVERVIEW 133
FIGURE 44 SWOT ANALYSIS 135

【レポートのキーワード】

コンパニオン診断、コンパニオン診断技術、ポリメラーゼ連鎖反応(PCR)、In situ ハイブリダイゼーション(ISH)、免疫組織化学(IHC)、医薬品

★調査レポート[世界のコンパニオン診断市場:ポリメラーゼ連鎖反応(PCR)、In situ ハイブリダイゼーション(ISH)、免疫組織化学(IHC)など] ( Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), & by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends & Forecasts to 2019 / MAM-BT-2698) 販売に関する免責事項
[世界のコンパニオン診断市場:ポリメラーゼ連鎖反応(PCR)、In situ ハイブリダイゼーション(ISH)、免疫組織化学(IHC)など] ( Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), & by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends & Forecasts to 2019 / MAM-BT-2698) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆